New pill could help immune system fight rare sarcomas
NCT ID NCT07014137
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental oral drug called ABSK043 in about 20 people with rare sarcomas (intimal sarcoma, head/neck angiosarcoma, or EHE). The drug blocks PD-L1, which may help the immune system recognize and kill cancer cells. The main goal is to see if tumors shrink and to check safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABSK043 (an oral drug that blocks PD-L1 to help the immune system attack cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for rare sarcomas that are hard to treat.
What could go wrong
This is a small, early-phase trial with only 20 people, so results may not apply widely. The drug is experimental and may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN- Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••